Not yet recruiting NCT07731685
A Phase Ib, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of VC004 Capsules for Pain in Bone Metastases
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: VC004 low dose, VC004 high dose, VC004 placebo.
- Who it may be relevant to
- Registry conditions: Pain in Bone Metastases. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This is a randomized, double-blind, placebo-controlled Phase Ib study evaluating the safety and efficacy of VC004 capsules for the relief of moderate-to-severe pain associated with bone metastases
Interventions
- Drug VC004 low dose
VC004 low dose BID - Drug VC004 high dose
VC004 high dose BID - Drug VC004 placebo
VC004 placebo BID
Primary outcome measures
- Change from baseline in the daily average pain intensity Numeric Rating Scale (NRS) score [Time frame: At Week 1, Week 2 and Week 4]
Eligibility criteria
Inclusion criteria
- Participants must understand and voluntarily sign the informed consent form (ICF);
- Male or female, aged ≥ 18 years;
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2;
- Life expectancy of ≥ 12 weeks, as assessed by the investigator;
- The participant is able to communicate well with the investigator, and is willing and able to comply with all scheduled visits, treatment plans, laboratory tests, and other study procedures.
Exclusion criteria
- The participant's pain is associated with oncologic emergencies, such as intestinal obstruction/perforation, spinal cord compression, epidural metastasis, or fracture or impending fracture of weight-bearing bones;
- The participant has known or suspected unstable brain metastases or leptomeningeal metastases；
- History of severe alcohol, analgesic, or narcotic drug abuse within 6 months prior to screening;
- Major surgery within 3 months prior to screening, or planned major surgery during the study period;
- Female participants who are planning to become pregnant, are pregnant, or are breastfeeding; or participants who are unwilling or unable to use effective contraception throughout the entire study period and for 3 months after the end of the study;
- Any other condition that, in the opinion of the investigator, would make the participant unsuitable for participation in this study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
China · 2 centers
- Zhongda Hospital,Affiliated to Southeast University — Nanjing
- Zhongda Hospital,Affiliated to Southeast University — Nanjing
Identifiers
NCT: NCT07731685 · VC004-104